Compile Data Set for Download or QSAR
Report error Found 1920 of ic50 for UniProtKB: P50750
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120943(US8716296, 89)
Affinity DataIC50: 0.00500nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120941(US8716296, 82)
Affinity DataIC50: 0.0150nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120934(US8716296, 2)
Affinity DataIC50: 0.0180nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120936(US8716296, 6 | US8716296, 5)
Affinity DataIC50: 0.0190nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120942(US8716296, 83)
Affinity DataIC50: 0.0290nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120935(US8716296, 3)
Affinity DataIC50: 0.0390nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120939(US8716296, 52)
Affinity DataIC50: 0.116nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120936(US8716296, 6 | US8716296, 5)
Affinity DataIC50: 0.173nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM126500(US8778951, 310 | US11591322, Compound NVP-2)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM126500(US8778951, 310 | US11591322, Compound NVP-2)
Affinity DataIC50: 0.514nMAssay Description:Inhibition of CDK9 (unknown origin) by Kinomescan methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444516(US10662186, Compound 38 | US10988476, Compound I-3...)
Affinity DataIC50: 0.920nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444516(US10662186, Compound 38 | US10988476, Compound I-3...)
Affinity DataIC50: 0.920nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180827(US9133171, 32)
Affinity DataIC50: 1nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50139171(Dinaciclib | MK-7965 | SCH-727965 | US11643396, Ex...)
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK9 (unknown origin) expressed in Sf9 insect cells using biotinylated peptide derived Histone H1 as substrate incubated for 1 hr in pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50193093(RGB-286638)
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120940(US8716296, 53)
Affinity DataIC50: 1.08nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167699(US9073922, 186 | US9796708, Example 186)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167699(US9073922, 186 | US9796708, Example 186)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of CDK9 (unknown origin) by LANCE ULight TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120938(US8716296, 51)
Affinity DataIC50: 1.25nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM25036(CHEMBL393525 | N'-[(1E)-{6-bromoimidazo[1,2-a]pyri...)
Affinity DataIC50: 1.40nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM694495(US20240293557, Compound SF-8-140)
Affinity DataIC50: 1.66nMAssay Description:CDK9 activity assays were performed by Nanosyn using a microfluidics mobility shift platform. In this assay, a fluorescently labeled substrate is inc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/21/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50193104(CHEMBL3905910)
Affinity DataIC50: 1.70nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50263013(CHEMBL4079206)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human CDK9More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167858(US9073922, 355)
Affinity DataIC50: 2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167859(US9073922, 356)
Affinity DataIC50: 2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167860(US9073922, 357)
Affinity DataIC50: 2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180815(US9133171, 20)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180819(US9133171, 24)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 31 | US9133171, 30 | US9133171, 29)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180836(US9133171, 41)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180837(US9133171, 42)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180843(US9133171, 48)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180799(US9133171, 14 | US9133171, 13 | US9133171, 4)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180823(US9133171, 28)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 31 | US9133171, 30 | US9133171, 29)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 31 | US9133171, 30 | US9133171, 29)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180851(US9133171, 56)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180853(US9133171, 58)
Affinity DataIC50: 2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50363196(CHEMBL1944698)
Affinity DataIC50: 2nMAssay Description:Inhibition of human CDK9More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50600028(CHEMBL5190816)
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50113281(AT-7519 | US20240293557, Compound AMC-3-098)
Affinity DataIC50: 2.06nMAssay Description:CDK9 activity assays were performed by Nanosyn using a microfluidics mobility shift platform. In this assay, a fluorescently labeled substrate is inc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444542(US10662186, Compound 62 | US10988476, Compound I-6...)
Affinity DataIC50: 2.44nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444542(US10662186, Compound 62 | US10988476, Compound I-6...)
Affinity DataIC50: 2.44nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50186373(N-(5-(2-(cyclohexyloxy)pyrimidin-4-yl)thiazol-2-yl...)
Affinity DataIC50: 2.5nMAssay Description:Inhibition of CDK9More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM354126(trans-4-{4-[5-fluoro-4-(5-fluoro-2-methoxyphenyl)-...)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM354126(trans-4-{4-[5-fluoro-4-(5-fluoro-2-methoxyphenyl)-...)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of CDK9 (unknown origin) by LANCE ULight TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
PubMed
TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM694490(US20240293557, Compound AMC-3-104)
Affinity DataIC50: 2.82nMAssay Description:CDK9 activity assays were performed by Nanosyn using a microfluidics mobility shift platform. In this assay, a fluorescently labeled substrate is inc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/21/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM694494(US20240293557, Compound CG-3-071)
Affinity DataIC50: 2.85nMAssay Description:CDK9 activity assays were performed by Nanosyn using a microfluidics mobility shift platform. In this assay, a fluorescently labeled substrate is inc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/21/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM164883(US9067888, 33)
Affinity DataIC50: 3nMpH: 7.5Assay Description:In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2016
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180812(US9133171, 19 | US9133171, 18 | US9133171, 17)
Affinity DataIC50: 3nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1920 total ) | Next | Last >>
Jump to: